MCRB

Company Overview — What Does Seres Therapeutics, Inc. Do?

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the treatment of clostridium difficile infection (CDI). It is also developing SER-155, a cultivated bacteria microbiome drug, which is Phase Ib clinical trial to reduce incidences of gastrointestinal infections, bloodstream infections, and graft versus host diseases in immunocompromised patients receiving allogeneic hematopoietic stem cell transplantation and solid organ transplants. In addition, the company engages in the development of SER-287 and SER-301 that are in Phase Ib to treat ulcerative colitis; SER-401 for patients with metastatic melanoma; and SER-262 to treat Clostridioides difficile infection. It has license and collaboration agreements with Nestec Ltd. and Memorial Sloan Kettering Cancer Center. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Seres Therapeutics, Inc. (MCRB) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Eric D. Shaff and employs approximately 330 people, headquartered in Cambridge, Massachusetts. With a market capitalization of $85M, MCRB is one of the notable companies in the Healthcare sector.

Seres Therapeutics, Inc. (MCRB) Stock Rating — Avoid (April 2026)

As of April 2026, Seres Therapeutics, Inc. receives a Avoid rating with a composite score of 22.9/100 and 1 out of 5 stars from the Blank Capital Research quantitative model.MCRB ranks #4,015 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Seres Therapeutics, Inc. ranks #696 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

MCRB Stock Price and 52-Week Range

Seres Therapeutics, Inc. (MCRB) currently trades at $8.32. The stock lost $0.39 (4.5%) in the most recent trading session. The 52-week high for MCRB is $29.98, which means the stock is currently trading -72.2% from its annual peak. The 52-week low is $0.36, putting the stock 2211.1% above its annual trough. Recent trading volume was 52K shares, suggesting relatively thin trading activity.

Is MCRB Overvalued or Undervalued? — Valuation Analysis

Seres Therapeutics, Inc. (MCRB) carries a value factor score of 21/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The trailing price-to-earnings ratio is 0.77x, compared to the Healthcare sector average of 23.63x — a discount of 97%. The price-to-book ratio stands at 1.92x, versus the sector average of 2.75x. The price-to-sales ratio is 241.71x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, MCRB trades at 4.88x EV/EBITDA, versus 6.34x for the sector.

At current multiples, Seres Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Seres Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Seres Therapeutics, Inc. (MCRB) earns a quality factor score of 9/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 248.3%, compared to the Healthcare sector average of -43.5%, which demonstrates strong shareholder value creation. Return on assets (ROA) comes in at 79.5% versus the sector average of -33.1%.

On a margin basis, Seres Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -6403.7% (sector: -66.1%). Net profit margin stands at 2337.3%, versus -58.7% for the average Healthcare stock. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

MCRB Debt, Balance Sheet, and Financial Health

Seres Therapeutics, Inc. has a debt-to-equity ratio of 213.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 2.56x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $48M.

MCRB has a beta of 15.12, meaning it is more volatile than the broader market — a $10,000 investment in MCRB would be expected to move 1411.7% more than the S&P 500 on any given day. The stability factor score for Seres Therapeutics, Inc. is 9/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Seres Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Seres Therapeutics, Inc. reported revenue of $351,000 and earnings per share (EPS) of $0.64. Net income for the quarter was $110M. Gross margin was 100.0%. Operating income came in at $-104M.

In FY 2025, Seres Therapeutics, Inc. reported revenue of $789,000 and earnings per share (EPS) of $0.64. Net income for the quarter was $6M. Operating income came in at $-94M.

In Q3 2025, Seres Therapeutics, Inc. reported revenue of $351,000 and earnings per share (EPS) of $0.94. Net income for the quarter was $8M. Operating income came in at $-22M.

In Q2 2025, Seres Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-2.27. Net income for the quarter was $-20M. Operating income came in at $-25M.

Over the past 8 quarters, Seres Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $0 to $351,000. Investors analyzing MCRB stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

MCRB Dividend Yield and Income Analysis

Seres Therapeutics, Inc. (MCRB) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

MCRB Momentum and Technical Analysis Profile

Seres Therapeutics, Inc. (MCRB) has a momentum factor score of 50/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 11/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.

MCRB vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Seres Therapeutics, Inc. (MCRB) ranks #696 out of 838 stocks based on the Blank Capital composite score. This places MCRB in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing MCRB against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MCRB vs S&P 500 (SPY) comparison to assess how Seres Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

MCRB Next Earnings Date

No upcoming earnings date has been announced for Seres Therapeutics, Inc. (MCRB) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy MCRB? — Investment Thesis Summary

The quantitative profile for Seres Therapeutics, Inc. suggests caution. The quality score of 9/100 flags below-average profitability. The value score of 21/100 indicates premium valuation. High volatility (stability score 9/100) increases portfolio risk.

In summary, Seres Therapeutics, Inc. (MCRB) earns a Avoid rating with a composite score of 22.9/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MCRB stock.

Related Resources for MCRB Investors

Explore more research and tools: MCRB vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MCRB head-to-head with peers: MCRB vs AZN, MCRB vs SLGL, MCRB vs VMD.